IGLV1 51 | ENSG00000211644 | NCBI 28820

Details for: IGLV1 51

Gene ID: 28820

Gene Type: Other - A known gene or region type that lacks a specific category. Includes immunoglobulin (Ig), T-cell receptor (TCR) gene segments, and repetitive elements.

Symbol: IGLV1 51

Ensembl ID: ENSG00000211644

Description: immunoglobulin lambda variable 1-51

Selected Context(s): Overall

Cell Significance Landscape

Display Count:

Contexts:

	Overall overall
	Basal cell carcinoma MONDO0020804
	Blood UBERON0000178
	\|— Blood COVID-19 UBERON0000178_MONDO0100096
	\|— Blood Healthy UBERON0000178_PATO0000461
	Bone marrow UBERON0002371
	\|— Bone marrow Healthy UBERON0002371_PATO0000461
	COVID-19 MONDO0100096
	Healthy PATO0000461

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)
Adaptive immune response
(GO:0002250)
Antigen binding
(GO:0003823)
Extracellular exosome
(GO:0070062)
Extracellular region
(GO:0005576)
Immune response
(GO:0006955)
Immunoglobulin complex
(GO:0019814)
Plasma membrane
(GO:0005886)

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

class switched memory B cell CL0000972

CSI 11.99

rCSI 8.95%

PRS 98.21
B cell CL0000236

CSI 8.35

rCSI 11.18%

PRS 93.78
IgA plasma cell CL0000987

CSI 7.39

rCSI 7.57%

PRS 95.02
IgG plasma cell CL0000985

CSI 6.16

rCSI 7.38%

PRS 96.61
plasmablast CL0000980

CSI 4.98

rCSI 3.91%

PRS 96.24
IgM plasma cell CL0000986

CSI 0.86

rCSI 3.87%

PRS 98.12

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Context Genes (max 20):

Interaction Source:

Pathway Categories (for ONTOLOGY source):

Baseline Cell Type:

Baseline Cell Context(s): Comma-separated if multiple.

Target Cell Type:

Target Cell Context(s): Comma-separated if multiple.

Legend:

Query Gene
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
Node Size: Proportional to Target Cell CSI magnitude
STRING PPI Edge
Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

Description

## Summary [IGLV1 51](/details-gene/28820), or Immunoglobulin Lambda Variable 1-51, is a V (variable) gene segment located on chromosome 22. It functions as a critical component in the assembly of the immunoglobulin lambda light chain. Its primary role is in the adaptive immune system, where it contributes to the vast diversity of antigen-binding sites on B-cell receptors and secreted antibodies. Expression data strongly indicates that [IGLV1 51](/details-gene/28820) is highly and specifically utilized within the B cell lineage, particularly in mature, antigen-experienced populations such as [class switched memory B cells](/details-cell/CL0000972) and antibody-producing [plasma cells](/details-cell/CL0000987), underscoring its fundamental role in humoral immunity. ## Cellular Roles and Expression Landscape The expression profile of [IGLV1 51](/details-gene/28820) is highly restricted to the B cell compartment, confirming its specialized function in the humoral immune response. **Overall**, the gene's significance is most pronounced in cells responsible for antibody production and immunological memory. Its highest significance is observed in [class switched memory B cells](/details-cell/CL0000972) (CSI: 11.99), suggesting a key role in the long-term recall response to pathogens. High significance is also noted in the broader [B cell](/details-cell/CL0000236) population (CSI: 8.35). Furthermore, its prominent expression in various antibody-secreting cell types, including [IgA plasma cells](/details-cell/CL0000987) (CSI: 7.39), [IgG plasma cells](/details-cell/CL0000985) (CSI: 6.16), and [plasmablasts](/details-cell/CL0000980) (CSI: 4.98), highlights its direct involvement in the generation of secreted immunoglobulins that mediate effector functions. This pattern firmly establishes [IGLV1 51](/details-gene/28820) as a core component of the antibody repertoire. ## Pathways and Molecular Function The functional annotations for [IGLV1 51](/details-gene/28820) are consistent with its role as a variable segment of an antibody light chain. Its primary molecular function is [antigen binding](/details-gene/GO:0003823), which is the basis for its involvement in the [adaptive immune response](/details-gene/GO:0002250). As part of an [immunoglobulin complex](/details-gene/GO:0019814) located on the [plasma membrane](/details-gene/GO:0005886) or in the [extracellular region](/details-gene/GO:0005576), its product participates in a wide array of immunological processes. Reactome pathway analysis further elucidates its central role in the [adaptive immune system](/details-gene/R-HSA-1280218). It is integral to pathways such as [signaling by the B cell receptor (BCR)](/details-gene/R-HSA-983705), which is the initial step in B cell activation upon antigen encounter. Downstream, antibodies containing this V-segment can trigger effector functions, including the [complement cascade](/details-gene/R-HSA-166658) and [Fcgamma receptor (FCGR) dependent phagocytosis](/details-gene/R-HSA-2029480). The gene's implication in pathways related to [infectious disease](/details-gene/R-HSA-5663205) and [parasite infection](/details-gene/R-HSA-9664407) reinforces its importance in host defense. ## Research Directions The specific function of [IGLV1 51](/details-gene/28820) as a germline V-gene segment suggests that its contribution to immunity is defined by the antigens its resultant antibodies can recognize. Understanding the prevalence and specificity of this segment in health and disease offers several avenues for research. ### Proposed Hypotheses 1. **Pathogen-Specific Repertoire Bias:** Due to its specific germline-encoded structure, the [IGLV1 51](/details-gene/28820) segment may be preferentially selected in the humoral immune response against a particular class of antigens, such as conserved epitopes on viral glycoproteins or bacterial polysaccharides. 2. **Role in Autoimmunity:** Antibodies utilizing the [IGLV1 51](/details-gene/28820) segment could be disproportionately represented in the pool of pathogenic autoantibodies found in certain autoimmune diseases, suggesting a structural predisposition for self-antigen recognition following somatic hypermutation. 3. **Biomarker for B-Cell Malignancies:** Clonal expansion of malignant [B cells](/details-cell/CL0000236), as seen in some lymphomas or multiple myelomas, may be characterized by the overuse of specific V-genes like [IGLV1 51](/details-gene/28820), potentially serving as a clonal marker for disease monitoring. ### Key Experiments To test the hypothesis of **Pathogen-Specific Repertoire Bias**, a powerful approach would be to perform high-throughput B-cell receptor (BCR) repertoire sequencing. This experiment would involve collecting peripheral blood from cohorts of individuals who have been vaccinated against or have recovered from distinct viral or bacterial infections (e.g., influenza, SARS-CoV-2, *Streptococcus pneumoniae*). Antigen-specific [memory B cells](/details-cell/CL0000972) could be isolated using fluorescently-labeled antigens. By sequencing the BCRs from these sorted populations, one could quantify the usage frequency of [IGLV1 51](/details-gene/28820) in the antigen-specific repertoire for each pathogen. A statistically significant enrichment of [IGLV1 51](/details-gene/28820) usage in the response to one pathogen compared to others would provide strong evidence for its specialized role in recognizing specific antigenic structures. ### Therapeutic Potential [IGLV1 51](/details-gene/28820) itself is not a direct therapeutic target. However, its product—the variable region of an antibody—is of immense therapeutic relevance. If antibodies containing the [IGLV1 51](/details-gene/28820) segment are identified as being protective against a specific pathogen, they could be developed as monoclonal antibody therapies. Conversely, if pathogenic autoantibodies or the BCRs on malignant B-cell clones are found to consistently use this segment, it could become a target for highly specific anti-idiotype therapies designed to eliminate only the disease-causing B-cell clones while sparing the rest of the immune system.

Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.